Glenmark Pharmaceuticals Ltd Stock Price Today (NSE: GLENMARK)
Fundamental Score
Glenmark Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Glenmark Pharmaceuticals Ltd share price today is ₹2038.80, up +0.00% on NSE/BSE as of 17 February 2026. Glenmark Pharmaceuticals Ltd (GLENMARK) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹54.77K (Cr). The 52-week high for GLENMARK share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 21.78x, GLENMARK is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.79% and a debt-to-equity ratio of 0.13.
Glenmark Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Glenmark Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of Glenmark Pharmaceuticals Share Price
The pharmaceutical sector, often viewed as defensive, can still experience volatility due to factors like patent expirations, regulatory changes, and research & development successes. This analysis focuses on the financial health of Glenmark Pharmaceuticals, specifically examining the current Glenmark Pharmaceuticals share price and key financial ratios. Currently, the share trades at ₹1934.800049 with a Price-to-Earnings (PE) ratio of 21.78.
A crucial aspect of evaluating a company's financial stability is its ability to generate returns on its capital. Glenmark Pharmaceuticals' Return on Capital Employed (ROCE) stands at 19.4%. This indicates the company's efficiency in utilizing its capital to generate profits. A ROCE of 19.4% suggests a relatively strong moat, indicating competitive advantages that allow Glenmark to earn higher returns compared to its cost of capital. This higher return can be reinvested to fuel further growth, creating a virtuous cycle.
Comparing Glenmark to its peers provides further context. For example, analyzing
Mankind Pharma Ltd alongside Glenmark necessitates evaluating management quality and strategic decision-making. Examining factors like new product pipelines, expansion strategies, and debt management policies across both companies helps assess their long-term growth prospects. A detailed comparison is important to evaluate the relative strengths and weaknesses of each organization to analyze whether Glenmark Pharmaceutical’s is relatively undervalued or overvalued when compared to Mankind Pharma Ltd.The PE ratio of 21.78 offers insight into how the market values Glenmark's earnings relative to other companies in the sector. It is important to place this within the context of broader market conditions and future earnings projections. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra and seeks to understand the current and future financial performance of Glenmark Pharmaceuticals. This analysis uses an observational approach. It is not a buy/sell recommendation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Glenmark Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLENMARK across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (15.79%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (16.68%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.78 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (333.45%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (76.10%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.13)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (15.81x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Institutional Confidence (FII+DII: 39.34%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Growth History (4.60% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-1882.86 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Glenmark Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Glenmark Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About GLENMARK (Glenmark Pharmaceuticals Ltd)
Glenmark Pharmaceuticals Ltd (GLENMARK) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹54.77K (Cr). Glenmark Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 15.79% and a ROCE of 19.40%. The debt-to-equity ratio stands at 0.13, reflecting the company's capital structure. Investors tracking GLENMARK share price can monitor key metrics including P/E ratio, promoter holding of 46.65%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
GLENMARK Share Price: Frequently Asked Questions
What is the current share price of Glenmark Pharmaceuticals Ltd (GLENMARK)?
As of 17 Feb 2026, 10:10 am IST, Glenmark Pharmaceuticals Ltd share price is ₹2038.80. The GLENMARK stock has a market capitalisation of ₹54.77K (Cr) on NSE/BSE.
Is GLENMARK share price Overvalued or Undervalued?
GLENMARK share price is currently trading at a P/E ratio of 21.78x, compared to the industry average of 31.77x. Based on this relative valuation, the Glenmark Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of GLENMARK share price?
The 52-week high of GLENMARK share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Glenmark Pharmaceuticals Ltd share price?
Key factors influencing GLENMARK share price include quarterly earnings growth (Sales Growth: 76.10%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Glenmark Pharmaceuticals Ltd a good stock for long-term investment?
Glenmark Pharmaceuticals Ltd shows a 5-year Profit Growth of 11.77% and an ROE of 15.79%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.13 before investing in GLENMARK shares.
How does Glenmark Pharmaceuticals Ltd compare with its industry peers?
Glenmark Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare GLENMARK share price P/E of 21.78x and ROE of 15.79% against the industry averages to determine competitive standing.
What is the P/E ratio of GLENMARK and what does it mean?
GLENMARK share price has a P/E ratio of 21.78x compared to the industry average of 31.77x. Investors pay ₹22 for every ₹1 of annual earnings.
How is GLENMARK performing according to Bull Run's analysis?
GLENMARK has a Bull Run fundamental score of 61.2/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GLENMARK belong to?
GLENMARK operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Glenmark Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for GLENMARK?
GLENMARK has an ROE of 15.79%, which indicates excellent management efficiency. ROE measures how efficiently Glenmark Pharmaceuticals Ltd generates profits from shareholders capital.
How is GLENMARK debt-to-equity ratio and what does it indicate?
GLENMARK has a debt-to-equity ratio of 0.13, which indicates conservative financing with low financial risk.
What is GLENMARK dividend yield and is it a good dividend stock?
GLENMARK offers a dividend yield of 0.13%, meaning you receive ₹0.13 annual dividend for every ₹100 invested in Glenmark Pharmaceuticals Ltd shares.
How has GLENMARK share price grown over the past 5 years?
GLENMARK has achieved 5-year growth rates of: Sales Growth 4.60%, Profit Growth 11.77%, and EPS Growth 11.77%.
What is the promoter holding in GLENMARK and why does it matter?
Promoters hold 46.65% of GLENMARK shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Glenmark Pharmaceuticals Ltd.
What is GLENMARK market capitalisation category?
GLENMARK has a market capitalisation of ₹54765 crores, placing it in the Large-cap category.
How volatile is GLENMARK stock?
GLENMARK has a beta of N/A. A beta > 1 suggests the Glenmark Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GLENMARK operating profit margin trend?
GLENMARK has a 5-year average Operating Profit Margin (OPM) of 16.68%, indicating the company's operational efficiency.
How is GLENMARK quarterly performance?
Recent quarterly performance shows Glenmark Pharmaceuticals Ltd YoY Sales Growth of 76.10% and YoY Profit Growth of 333.45%.
What is the institutional holding pattern in GLENMARK?
GLENMARK has FII holding of 20.73% and DII holding of 18.61%. Significant institutional holding often suggests professional confidence in the Glenmark Pharmaceuticals Ltd stock.